Study identifies target for disease hyper progression after immunotherapy in kidney cancer
Researchers find that cancer cells mimic myeloid cells to hide from the immune system and promote disease hyper progression after immunotherapy
Inhibiting the myeloid mimicry pathway along with immunotherapy improves antitumor outcomes in preclinical models
Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called “myeloid mimicry” to hide...
HER2-targeted therapy shows promising results in rare bile duct cancers
HER2-positive metastatic biliary tract cancer (BTC) is a rare and aggressive cancer with limited treatment options
Final results from the...
Researchers identify rare mutation that predicts strong immunotherapy response in colorectal cancer
A specific subset of POLE gene mutation, called loss-of-proofreading (LOP) mutations, makes colorectal tumors highly responsive to immunotherapy...
MD Anderson experts spotlight key immunotherapy advances at 2025 SITC Annual Meeting
Major themes include strategies to reprogram the tumor microenvironment and prevent cancer before it starts
New insights from AI-based imaging, B-cell biology and mRNA vaccine technology point to more personalized and long-lasting cancer immunotherapies
Research reveals that genetic mutations, neural signaling and microbiome composition play critical roles in modulating resistance to immunotherapy
NATIONAL HARBOR, MD, NOVEMBER 7,...
Comprehensive molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive...
New oral therapy shows early signs of safety and effectiveness in patients with advanced, treatment-resistant prostate cancer
Trial shows promising early results for HLD-0915, a first-in-class regulated induced proximity targeting chimera (RIPTAC) treatment
Metastatic...
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression
First head-to-head study...
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal...